Today they jump on the dndn bandwagon, announce a patent on a synthetic (modified) common cancer antigen. It's more immunogenic!
But of all, the failure to deliver another Purdue-type agreement bothers me the most. Further, how long would it take to sign an agreement with a mouse or phage antibody company for all their highly characterized internal antigens? If you have Word, you just push the copy and print commands. Must be something else at work.
>>FRAMINGHAM, Mass., Oct. 24 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO - news) today announced the issuance of U.S. Patent No. 6,306,640 for the discovery of novel, synthetic peptides and pharmaceutical compositions useful as therapeutic melanoma vaccines.
Discovered by Genzyme Molecular Oncology's antigen discovery group led by Charles A. Nicolette, Ph.D., the peptide ligands are superior immunogens when compared to the native gp100 epitope. The newly issued melanoma antigen patent provides synthetic peptide ligand variants of the 209 T cell epitope of gp100 that may be useful in developing potent melanoma vaccines.<<
Wilder, no longer a shareholder |
